Jenoptik Q2 Earnings Call Highlights

Jenoptik Q2 Earnings Call Highlights Written by MarketBeat August 12, 2026 Add As Preferred Source Share Share Share This Article Link copied to clipboard. Close Image from MarketBeat Media, LLC. Key Points Orders and backlog surged: First-half order intake rose more than 50% year over year, lifting the book-to-bill ratio to 1.4 and the backlog to approximately €825 million. Growth was led by Semiconductor & Advanced Manufacturing and Biophotonics. Profitability improved sharply: First-half revenue grew 1%, while EBITDA increased more than 25% to about €99 million and the EBITDA margin expanded by nearly 400 basis points. Semiconductor demand and cost reductions supported the improvement, although automotive weakness weighed on Metrology & Production Solutions. 2026 outlook raised within prior ranges: Jenoptik now expects revenue growth of 5%–9% and an EBITDA margin of 20%–21%, both in the upper half of its previous guidance. Management is prioritizing capacity expansion to address the larger backlog but cautioned that exceptionally strong first-half semiconductor and Biophotonics orders may not continue at the same pace. MarketBeat previews top five stocks to own in September . Jenoptik ETR: JEN reported a return to revenue growth and a sharp improvement in profitability in the first half of 2026, supported by demand in its semiconductor-focused operations and strong order activity in Biophotonics. The company also raised the specificity of its full-year outlook, forecasting revenue growth toward the upper half of its previous range. New Chief Executive Officer Dominic Dorfner, who officially joined the company on Aug. 1, said he had begun visiting Jenoptik sites and meeting employees, customers and other stakeholders. He said photonics offers “a lot of growth potential” and that his immediate focus would be listening and gaining a fuller understanding of the business. Get Jenoptik alerts: Sign Up Dorfner also said Jenoptik is conducting an update of its strategy process. The executive board expects to communicate key findings and outcomes “towards the end of the year at the earliest,” he said. Orders and backlog rise sharply Dr. Prisca Havranek-Kosicek said group order intake rose by more than 50% year over year in the first half, exceeding management’s expectations. The increase was led by Semiconductor & Advanced Manufacturing and Biophotonics, lifting the group’s book-to-bill ratio to 1.4 and expanding the order backlog to about €825 million. Semiconductor & Advanced Manufacturing benefited from demand in lithography and continued customer activity in semiconductor inspection. While second-quarter orders were below the first-quarter level, management noted that the first quarter had included a large annual order. Management said the semiconductor industry ramp-up remains in full swing, though it cautioned that the exceptionally strong order levels recorded in the first half should not necessarily be expected to continue at the same level in the next two quarters. Havranek-Kosicek said some semiconductor customers may place orders in part to secure capacity during the industry ramp-up, but she did not characterize this as a specific pull-forward of orders from the second half. Biophotonics order intake increased 45% year over year in the first half. The business benefited from strong demand in defense-related markets and a multi-year MedTech order in the low double-digit-million-euro range. Management said the large MedTech order was not related to life sciences or dentistry, but did not provide further details because of its concentrated key-account customer base. Havranek-Kosicek said some early-order effects tied to geopolitical uncertainty were seen mainly in Biophotonics, including defense, life sciences and MedTech. She also cautioned that quarterly order intake in the unit can be volatile because defense orders can be concentrated and multi-year in nature. Semiconductor & Advanced Manufacturing order activity was dr...